Back to search

Peptide record

TPDB22269

Antibacterial Hemolysis Toxicity standard
4 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB22269
Antibacterial Hemolysis Toxicity
Anti-infective peptides Toxicity and safety peptides
Peptipedia PD_Hemolysis
standard
No
A 4-aa standard natural multi-activity (Antibacterial, Hemolysis, and Toxicity) peptide sequence curated from Peptipedia and PD_Hemolysis, with an available 3D structural model.
Sequence
KRIW
Physicochemical Analysis
C29H47N9O5
ANDCEQGHLMFPSTYV
RIKW
601.75
11.49
2
0
2
+2
-0.36
-1.200
97.50
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
5500
914.00
0
Residue Composition
number
0
A
1
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
1
I
0
L
1
K
0
M
0
F
0
P
0
S
0
T
1
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 1 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 1 L: 0 K: 1 M: 0 F: 0 P: 0 S: 0 T: 0 W: 1 Y: 0 V: 0
Chemical Descriptors
4
C29H47N9O5
601.75
11.49
+2
-0.36
-1.200
Evidence Records 5 records
Evidence 1 Activity

Activity

50% Hemolysis
Toxicity
<25 µM
Hemolytic Cytotoxic
50% Hemolysis | <25 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Short and Robust Anti-Infective Lipopeptides Engineered Based on the Minimal Antimicrobial Peptide KR12 of Human LL-37. | ACS Infect Dis | 2021
Evidence 2 Activity

Activity

50% Hemolysis
Toxicity
30 µM
Hemolytic Cytotoxic
50% Hemolysis | 30 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Short and Robust Anti-Infective Lipopeptides Engineered Based on the Minimal Antimicrobial Peptide KR12 of Human LL-37. | ACS Infect Dis | 2021
Evidence 3 Activity

Activity

50% Hemolysis
Toxicity
150 µM
Hemolytic Cytotoxic
50% Hemolysis | 150 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Short and Robust Anti-Infective Lipopeptides Engineered Based on the Minimal Antimicrobial Peptide KR12 of Human LL-37. | ACS Infect Dis | 2021
Evidence 4 Activity

Activity

50% Hemolysis
Toxicity
>200 µM
Hemolytic Cytotoxic
50% Hemolysis | >200 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Short and Robust Anti-Infective Lipopeptides Engineered Based on the Minimal Antimicrobial Peptide KR12 of Human LL-37. | ACS Infect Dis | 2021
Evidence 5 Hemolysis

Source & Reference

PD_Hemolysis
PD_Hemolysis